Introduction The Outcome Measures in Rheumatology Clinical Trials (OMERACT) Rheumatology Common Toxicity Criteria (RCTC) version 2.0 was published in 2007 by the OMERACT Drug Safety Working Group, building on limited experience with RCTC version 1.0, to facilitate standardization of assessment (grading) and reporting of adverse events (AEs) commonly seen in rheumatic disease clinical trials (Woodworth et al. in J Rheumatol 34:1401-1414 , 2007 .
Use of RCTC 2.0 in practice exposed inaccuracies/ overlaps in laboratory result ranges (which could impact grading) as well as omission of adverse event terms now recognized to occur commonly with newer drugs in rheumatic disease clinical trials.
We provide a corrected version, RCTC 2.1, and recommend a comprehensive revision as soon as feasible.
Introduction
Grading of adverse events (AEs) in clinical trials is important when analyzing the safety profiles of investigational medications [2, 3] . However, while there is a standard regulatory definition of seriousness [4] , there is no universally accepted method for assessing the severity of AEs in rheumatology clinical trials. This lack of a common understanding of levels of severity leads to heterogeneity of reporting, potentially limiting the validity of safety data analyses, and making comparison of potential harms of investigational agents across indications, or different agents within an indication, unclear. To address this issue, the Rheumatology Common Terminology (originally "Toxicity") Criteria (for AEs) (RCTC) version 2.0 was published in 2007 with the aim of addressing these issues [1] , taking into account the (default) use of the oncology Common Terminology Criteria for Adverse Events (CTCAE) [5] . Despite its publication in 2001, RCTC version 1.0 [6] had not been implemented in rheumatology clinical trials, possibly due to experience of pharmaceutical companies with the CTCAE. Nevertheless, in contrast to the CTCAE, which is an extensive catalogue of AEs seen in oncology clinical trials, RCTC 2.0 provides grading guidance that is more clinically appropriate for AEs seen in rheumatology clinical trials. It also provides guidance for assessment of the severity of any reported AEs by including definitions for grades 1-5 for any AEs not specifically listed in RCTC 2.0.
More recently, the grading of AEs is advocated by PhUSE (Pharmaceutical Users Software Exchange) [3] , which strongly advocated standardized methods for safety data collection and grading. In addition, Transcelerate Biopharma [7] , an international organization whose mission is to collaborate across the global biopharmaceutical research and development community, has provided a link (https ://www. cdisc .org/stand ards/thera peuti c-areas /disea se-area/autoi mmune ) on its website to an initiative (Clinical Data Interchange Standards Consortium [CDISC]) to standardize collection and reporting of data for autoimmune disease clinical trials. According to the website, working groups engage patients, healthcare practitioners, global health authorities, clinical investigators, academic research institutions, clinical research organizations, and other industry stakeholders to improve the consistency of safety data collection and interpretability of safety data analyses.
The reference standard in this effort appears to be the (oncology) CTCAE [5] . This instrument incorporates standardized and validated measurements for reporting AEs and has standardized some objective measurements of severity relevant to oncology clinical trials. However, it was developed for oncology clinical trial reporting, and the severity of events acceptable in an oncology indication differs from what is acceptable for non-oncologic (e.g., rheumatologic) indications. Further, the CTCAE system is complex, composed of almost 150 pages [4] .
In this report, we describe our experience with the realworld application of the RCTC 2.0 in UCB Pharma rheumatologic/autoimmune disease clinical development programs, as well as those in inflammatory bowel disease and psoriasis. Our objectives were to (1) provide the first report of the use of RCTC 2.0 in UCB multinational pivotal clinical trials; (2) report immediately correctable errors identified in RCTC 2.0 and provide a corrected version-RCTC 2.1 (see Electronic Supplementary Material Appendix 1)-for immediate use; and (4) identify a preliminary list of clinically relevant AEs commonly seen in trials of drugs developed for rheumatologic and autoimmune indications that were not included in RCTC 2.0, as well as identifying the need for revision of the RCTC 2.0/2.1.
Methods
RCTC 2.0 was used to assess safety data in three large phase III trials of epratuzumab in systemic lupus erythematosus (SLE) (SL009, SL0010, SL0012), one phase III trial of certolizumab pegol in axial spondyloarthritis (axSpA) (AS001), and one phase III trial of certolizumab pegol in psoriatic arthritis (PsA) (PSA001) (total N = 3558 patients) ( Table 1 ). The US Food and Drug Administration (FDA) agreed to the use of the RCTC in specific analyses of these trials. The axSpA and PsA trials were submitted to the FDA as part of a regulatory filing, but the SLE trial results were not submitted because the trials did not support efficacy.
The original trials analyzed all followed International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and Good Clinical Practice (GCP) guidelines. The databases used for these analyses contained only de-identified aggregate data and therefore no ethical approvals were required. In our analysis, we examined the occurrence of markedly abnormal (i.e., clinically relevant; grade 3-4 RCTC criteria) laboratory abnormalities, and identified shifts over time among laboratory severity grades. Identification and grading of abnormal laboratory results for severity required statistical programming, both for accuracy and avoidance of potential biases. Laboratory data were examined as objective measures rather than more subjective symptoms, although the latter were included where possible (e.g., upper respiratory tract infections [URIs]).
Descriptive statistics were used to compare laboratory results. When appropriate, shift tables were used to compare changes among treatment groups. All relevant rheumatic clinical trial safety databases were examined (regardless of use of RCTC 2.0) to determine the most common AEs across all treatment groups (including placebo groups) and across all indications (rheumatoid arthritis, PsA, axSpA, psoriasis, Crohn's disease; N = 11,997). To examine whether there were inadvertent omissions in the RCTC 2.0, the 15 most often reported AEs (AEs with all severities, moderate AEs, severe AEs, serious AEs) were identified and compared to the RCTC 2.0 [1] and CTCAE 4.03 [5] listings (Table 2 ).
Results
RCTC 2.0 fulfilled its intended use-to enable reporting of severity of AEs as listed. For example, in one trial, imbalances between treatment groups were observed with respect to out-of-range aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values. However, analysis of only markedly abnormal values revealed no imbalance between treatment groups for these abnormal laboratory values. In another trial, analysis initially revealed differences between treatment groups in markedly abnormal creatine phosphokinase (CPK) values (> 4 × upper limit of normal) based on laboratory parameters only. Once the values were placed into a clinical context as described by RCTC 2.0, the apparent signal could be appropriately placed into context, as no values qualifying for grade 3 or 4 abnormalities were found once the full RCTC 2.0 definition was applied.
Some inconsistencies were noted while compiling the laboratory AE results, as highlighted in Fig. 1 . Correcting these inconsistencies is important for clarity and, thus, we provide these in the revised RCTC (RCTC 2.1), available in the Electronic Supplementary Material Appendix. We also identified several clinically relevant omissions in RCTC 2.0, which were not appreciated until RCTC 2.0 was used in clinical trials of drugs approved for use since 2007. For example, lipid abnormalities and calculated creatinine clearance are not included in RCTC 2.0. Some specific infections, e.g., tuberculosis, other specific opportunistic infections, some specific viral infections (e.g., Herpes zoster) or infectious 'syndromes' (e.g., sepsis, Mycobacterium avium complex), were either not included or not gathered together into easily recognized groupings. The analysis of the most common AEs in studies conducted in rheumatologic/autoimmune indications showed that RCTC 2.0 does not include many of the common AEs observed in rheumatologic studies (e.g., URIs, injection-site reactions) ( Table 2 ).
Discussion
To our knowledge, this is the first report examining the programmatic application of RCTC 2.0. It is intended as a case study of the real-world performance of RCTC 2.0 in autoimmune disease clinical trials conducted by a single multinational pharma company. We have identified immediately correctable errors in RCTC 2.0 and provide a corrected version for immediate use (Electronic Supplementary Material Appendix 1). In addition, we have developed a preliminary list of clinically relevant AEs commonly seen in clinical trials of drugs developed for autoimmune diseases, and we have begun to characterize the need for revision of RCTC 2.0. RCTC 2.0 incorporates clear and simplified AE definitions and specific criteria for severity estimations in rheumatic diseases with more appropriate thresholds for determination of abnormalities than those in the CTCAE. For example, the hemoglobin thresholds for grade 2, 3, and 4 abnormalities in the CTCAE are < 10 g/dL independent of prior value, whereas grading in RCTC is defined by a decrease of hemoglobin. Importantly, this instrument facilitated the safety analysis of laboratory abnormalities to differentiate treatment from control. Furthermore, examination of clinical signs and symptoms along with laboratory abnormalities, when collected according to RCTC 2.0 guidance, enabled determination of the relevance of observed laboratory abnormalities.
We have not been able to identify any previous publications regarding systematic or standardized safety reporting specifically in rheumatology clinical trials. The Consolidated Standards for Reporting Trials (CONSORT) statement with checklists for all clinical trials reporting standards, originally published in 2001 and revised in 2010, had only one statement on reporting "Harms" [8] . In 2004, Ioannidis et al. [2] elaborated this statement to provide additional points, including reporting severity. This statement suggested that a systematic approach with prospectively defined severity, such as that intended by RCTC 2.0, would enable more objective and consistent descriptions of safety profiles.
We also identified gaps in the data collected using RCTC 2.0. At the time this instrument was developed in 2006, the importance of lipid abnormalities in rheumatologic disease was not fully appreciated, as safety data from tocilizumab [9, 10] . Also, immunoglobulin levels were not included in RCTC 2.0, as abnormalities were not identified until rituximab rheumatoid arthritis clinical development reports. Estimated glomerular filtration rates were not initially included when RCTC 2.0 was published because the accuracy of the method of calculation was not established. An analysis of the most common AEs occurring in studies conducted in rheumatological indications showed that most of these common AEs are not described in detail in RCTC 2.0. These gaps suggest the need for regular review of safety issues in rheumatology and regular revision of RCTC 2.0. This report has some relevant strengths. It is the first published examination of the performance of RCTC 2.0. Although we are aware of at least 25 other studies using this AE severity scale instrument in rheumatic diseases, having reviewed citations of our 2007 article in PubMed (see Electronic Supplementary Material Appendix 2 for a list), specific analysis of the performance of RCTC 2.0 is not reported in any of them. Also, by examining the real-world use of this instrument, we have been able to correct several errors and clarify aspects of the instrument (available online as RCTC 2.1 in Electronic Supplementary Material Appendix 1), making it more accurate and usable. In addition, this work has given impetus to initiating an Outcome Measures in Rheumatology Clinical Trials (OMERACT)-consistent effort to include all appropriate stakeholders, including patients, in a comprehensive update of this instrument, which will be published as RCTC 3.0 in the future.
This report also has some limitations. First, the data are from a single sponsor, limiting the generalizability of the results, although most corrections reflect errors, which are independent of the data per se. Second, direct cross-correlation between clinical AE data and laboratory values was not possible in these data. Third, grades 1 and 2 AEs that require follow-up for evaluation within 1-2 weeks were only assessed for reporting at approximately monthly intervals, introducing some possibility of reporting bias. We propose and have implemented corrections for the inconsistencies noted, available as RCTC 2.1 in Electronic Supplementary Material Appendix 1.
While the RCTC has been cited in more than 25 publications (as listed in Electronic Supplementary Material Appendix 2), we acknowledge that this list represents a relatively small fraction of the trials completed since the publication of RCTC 2.0 in 2007. Since implementation was voluntary, we also acknowledge that there was no systematic promotion by a collaborative organization such as the Eastern Cooperative Oncology Group (ECOG) has done with CTCAE. The availability of standardized, uniformly defined severity assessments, as in RCTC 2.0, can improve consistency of grading, help ascertain the clinical relevance of AEs relative to placebo treatment, and facilitate comparisons across studies, treatments, and diseases. Such methodology is consistent with the FDA's recommendation to standardize safety data collection and reporting [6] , as is the case for the European Medicines Agency (EMA) [11] , as well as international collaborative groups such as PhUSE [3] and Transcelerate Biopharma/CDISC [7] , established to standardize and streamline clinical trial conduct and reporting.
Conclusions and Recommendations
RCTC 2.0 performed as intended despite some inaccuracies and omissions that were identified (and have now been corrected). We provide a corrected version, RCTC 2.1, in Electronic Supplementary Material Appendix 1. We also recommend comprehensive revision of RCTC 2.0 to include AEs that have been recognized to occur in autoimmune disease clinical trials evaluating targeted drugs since RCTC 2.0 was published. Results of future research should include a revised RCTC 2.0 to facilitate standardized assessment and reporting of AEs, together with an implementation plan. It will also be useful to include database structures that enable algorithmic connections between laboratory values and relevant clinical events.
Creating a user-friendly instrument to standardize grading of AEs will enable accurate comparison of the safety profiles of treatments for rheumatic/autoimmune diseases. Based on our observations, periodic maintenance of the revised instrument will also be important. There is a thorough formal and international OMERACT process that is underway to develop a Rheumatology Common Terminology for Adverse Events (RCTCAE), comparable to the oncology CTCAE [12] . The OMERACT process includes all concerned stakeholders, including, but not limited to, methodologists, clinicians, clinical trialists, regulators, and patients. Fig. 1 Snapshot from "Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0" [1] showing content errors, with correction of formatting errors [1] . ALT alanine aminotransferase, AST aspartate aminotransferase, ECG electrocardiogram, Hgb hemoglobin, LDH lactate dehydrogenase, LLN lower limit of normal, ULN upper limit of normal, WBC white blood cells ◂ past chair, OMERACT Drug Safety Working Group; Brian Kilgallen, former employee and stockholder of UCB; Daniel E. Furst, Grant/Research Support: BMS, Pfizer, Roche/Genentech; Consultant: Novartis, Pfizer, Roche/Genentech, Sanofi; Speakers Bureau (CME or nonpromotional only): none; no stocks, royalties, direct financial holding, expert testimony, or board of directors.
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